Giant cell myocarditis and cardiac sarcoidosis – update 2015

Česká verzia

Authors: M. Kubánek ¹; L. Voska ²
Authors place of work: Klinika kardiologie, Kardiocentrum, IKEM, Praha ¹; Pracoviště klinické a transplantační patologie, Transplantcentrum, IKEM, Praha ²
Published in the journal: Kardiol Rev Int Med 2015, 17(4): 295-299
Category: Cardiology Review

Summary

Giant cell myocarditis (GCM) and cardiac sarcoidosis are rare forms of myocarditis resistant to conventional management of heart failure and arrhythmias. GCM usually presents as fulminant myocarditis or subacute progressive non-ischemic heart failure. Advanced atrioventricular blockade and/ or ventricular tachycardias either accompany the aforementioned heart failure syndromes or represent predominant clinical manifestations of GCM. Except for the fulminant clinical course, cardiac sarcoidosis has a clinical presentation similar to GCM. However, its progression is slower, usually across a time interval of several months. The diagnosis of GCM is based mainly on endomyocardial biopsy. In contrast, endomycardial biopsy has a low sensitivity for the diagnosis of cardiac sarcoidosis. In the case of non-diagnostic endomyocardial biopsy, we need histological detection of extracardiac sarcoidosis and signs of cardiac involvement revealed by magnetic resonance imaging or positron emission tomography to diagnose cardiac sarcoidosis. Immunosuppressive treatment is a key component of the management of both diseases. Non-pharmacologic methods of heart failure and arrhythmia management are often necessary.

Keywords:
giant cell myocarditis – cardiac sarcoidosis

Zdroje

1. Cooper LT, Baughman KL, Feldman AM et al. The role of endomyocardial biopsy in the management of cardiovascular disease. AHA/ ACCF/ ESC scientific statement. Eur Heart J 2007; 28: 3076–3093. doi:10.1093/ eurheartj/ ehm456.

2. Caforio AL, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636–2648. doi: 10.1093/ eurheartj/ eht210.

3. Cooper LT. Myocarditis. N Engl J Med 2009; 360: 1526–1528. doi: 10.1056/ NEJMra0800028.

4. Cooper LT. Idiopathic giant cell myocarditis. In: Cooper LT (ed.) Myocarditis. From bench to bedside. Totowa, New Jersey: Humana Press 2003: 405–420.

5. Bennett MK, Gilotra NA, Harrington C et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000–2009 clinical perspective. Circ Heart Fail 2013; 6: 676–684. doi: 10.1161/ CIRCHEARTFAILURE.112.000087.

6. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18: 733–746. doi: 10.1007/ s10741-012-9358-3.

7. Kodama M, Matsumoto Y, Fujiwara M et al. A novel experimental model of giant cell myocarditis induces in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990; 57: 250–262.

8. Kodama M, Matsumoto Y, Fujiwara M. In vivo lymphocyte-mediated myocardial injuries demostrated by adoptive transfer of experimental autoimmune myocarditis. Circulation 1992; 85: 1918–1926.

9. Cooper LT jr, Berry GJ, Shabetai R. Multicentre giant cell myocarditis study group investigators. Idiopathic giant-cell myocarditis-natural history and treatment. N Engl J Med 1997; 336: 1860–1866.

10. Kandolin R, Lehtonen J, Salmenkivi K et al. Diag-nosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013; 6: 15–22. doi: 10.1161/ CIRCHEARTFAILURE.112.969261.

11. Shields RC, Tazelaar HD, Berry GJ et al. The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail 2002; 8: 74–78. doi: 10.1054/ jcaf.2002.32196.

12. Cooper LT jr, Hare JM, Tazelaar HD et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102: 1535–1539. doi: 10.1016/ j.amjcard.2008.07.041.

13. Grabmaier U, Brenner C, Methe H et al. An alternative immunosuppressive regimen to prolong transplant free survival in a patient with giant cell myocarditis. Int J Cardiol 2013; 168: e27–e28. doi: 10.1016/ j.ijcard.2013.05.078.

14. Chaudhry MA, Correa A, Lee C et al. Modern day management of giant cell myocarditis. Int J Cardiol 2015; 178: 82–84. doi: 10.1016/ j.ijcard.2014.10.131.

15. Cooper LT. Cardiac sarcoidosis. In: Cooper LT (ed.) Myocarditis. From bench to bedside. Totowa, New Jersey: Humana Press 2003: 421–436.

16. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010; 52: 336–346. doi: 10.1016/ j.pcad.2009.11.010.

17. Kron J, Ellenbogen KA. Cardiac sarcoidosis: Contemporary review. J Cardiovasc Electrophysiol 2015; 26: 104–109. doi: 10.1111/ jce.12552.

18. Hajšl M, Sedloň P, Černohous M et al. Sarkoidóza srdce jako příčina náhlé srdeční smrti. Cor Vasa 2013; 55: e78–e81. doi: 10.1016/ j.crvasa.2012.08.006.

19. Kandolin R, Lehtonen J, Airaksinen J et al. Cardiac sarcoidosis. Epidemiology, characteristics and outcome over 25 years in a nationwide study. Circulation 2015; 131: 624–632. doi: 10.1161/ CIRCULATIONAHA.114.011522.

20. Nery PB, Beanlands RS, Nair GM et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014; 25: 875–881. doi: 10.1111/ jce.12401.

21. Kumar S, Barbhaiya C, Nagashima K et al. Ventricular tachycardia in cardiac sarcoidosis. Characterisation of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015; 8: 87–93. doi: 10.1161/ CIRCEP.114.002145.

22. Okura Y, Dec GW, Hare LM et al. A clinical and histopathologic comparison of cardiac sarcoidosis of sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 2003; 41: 322–329. doi:10.1016/ S0735-1097(02)02715-8.

23. Yazaki Y, Isobe M, Hiroe M et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006–1010. doi: 10.1016/ S0002-9149(01)01978-6.

24. Chiu CZ, Nakatani S, Zhang G et al. Prevention of left ventricular remodeling by long-term corticosteriod therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005; 95: 143–146. doi: 10.1016/ j.amjcard.2004.08.083.

25. Sadek MM, Yung D, Birnie DH et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 2013; 29: 1034–1041. doi: 10.1016/ j.cjca.2013.02.004.

26. Birnie DHS, Bobun F, Cooper J et al. HRS expert consensus statement on diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1305–1323. doi: 10.1016/ j.hrthm.2014.03.043.

27. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 2007; 26: 714–717. doi: 10.1016/ j.healun.2007.05.006.